When the Primary Endpoint Changes Mid-Trial: The Amendment Playbook Sponsors Get Wrong
An intra-arterial alteplase trial changed its primary outcome at month 12 after 283 enrollments. Here's the clinops reality of...
Clinical Trial Operations
The Screen Failure You Can Prevent Before the Patient Leaves Home
Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...
Early Termination No Longer Means Failure. It Means the Trial Was Working.
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...
When the Sponsor’s IT Goes Down, Your Trial Goes With It
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...
When a Sponsor Switches Technology Platforms, the Site Feels It First
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring gaps nobody budgeted....
The 82x ROI Claim Every Oncology Sponsor Is About to Misread
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...
Daraxonrasib’s Resistance Map Is a Blueprint for How Oncology Trials Should Be Designed
Daraxonrasib's Phase 3 data in pancreatic cancer reveals how ctDNA-guided resistance profiling can reshape adaptive trial design—before acquired resistance…
The ICON-Anthropic Deal Will Reach Your Site Before You’re Ready for It
ICON's multi-year Claude deployment will reshape eTMF workflows, protocol timelines, and site data ops. Here's what coordinators need to...
AI Drug Discovery Has $8.9 Billion in Hype and Zero FDA Approvals: When Does the Bill Come Due?
AI drug discovery raised $8.9B in 2024, yet no AI-discovered drug holds FDA approval. The gap between algorithmic promise...
Glofitamab Plus Englumafusp Alfa: When Phase 1 Data Rewrites the Combination Therapy Playbook
A Nature Medicine phase 1 trial pairs glofitamab with CD19-4-1BBL co-stimulation in r/r B-NHL, producing efficacy signals that challenge...